About Proven Process

Company History

Proven Process is unique in the medical device contract R&D and OEM marketplace because exceptional medical device development and manufacturing is all we do. Founded in 1994 as the East Development Group, Proven Process has built in results for a wide variety of companies from high profile clients such as C.R. Bard, Boston Scientific, and Pfizer to small start-ups poised to make their names in the industry. The common thread in each client relationship is the value Proven Process brings from day one, tailored to the client’s needs and maximized to the client’s benefit.
 
 
Over the years, the company has had many proud moments, including being awarded a NIST Advanced Technology Program Grant. But the best rewards come from seeing our clients succeed with devices brought to market with the help of Proven Process. These include:
 


National institute of standards and technology/advanced technology program grant winning device

Totally Implantable Blood Pressure Sensor As a joint venture, Proven Process and APEX Medical have successfully completed initial animal tests of their totally implantable blood pressure device that will optimize operations of Left Ventricular Assist Devices (LVADs). Made of titanium, the device is being developed in part with funding awarded by the U.S. Department of Commerce's National Institute of Standards and Technology/Advanced Technology Program, following a national competition.

The device is the only known blood pressure monitor in development designed to fully integrate with an LVAD to assure direct, continuous measurement of blood pressure. An LVAD is used to treat congestive heart failure by working alongside a weakened heart, helping by pumping blood from the left ventricle. Five million Americans suffer from congestive heart failure today and 400,000 more are diagnosed with the disease each year. However, only about 2,500 hearts are available each year in the US for transplant, and as the population ages the incidence of heart disease is expected to increase.